Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.

Khanna, Vishesh; Pierce, Scott T; Dao, Kim-Hien T; Tognon, Cristina E; Hunt, David E; Junio, Brian; Tyner, Jeffrey W; Druker, Brian J.

Afiliação

Khanna V; Knight Cancer Institute, Oregon Health & Science University ; Howard Hughes Medical Institute Medical Research Fellows Program, Howard Hughes Medical Institute ; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University.
Pierce ST; Department of Hematology/Oncology, Saint Joseph Hospital.
Dao KH; Knight Cancer Institute, Oregon Health & Science University.
Tognon CE; Knight Cancer Institute, Oregon Health & Science University.
Hunt DE; Saint Joseph Hospital Laboratory, Saint Joseph Hospital.
Junio B; Knight Cancer Institute, Oregon Health & Science University.
Tyner JW; Knight Cancer Institute, Oregon Health & Science University.
Druker BJ; Knight Cancer Institute, Oregon Health & Science University ; Howard Hughes Medical Institute Investigator Program, Howard Hughes Medical Institute ; Division of Hematology & Medical Oncology, Oregon Health & Science University ; Department of Cell, Developmental & Cancer Biology, Or

Cureus ; 7(12): e414, 2015 Dec 17.

Article em En | MEDLINE | ID: mdl-26870618